Phio Pharmaceuticals Corp. PHIO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
60/100
Moderate

Ranked against 712 peers in Biotechnology

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive … Full PHIO analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.96), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.92), providing operational cushion.

Key risks

  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.
  • Inconsistent Cash Generation Cash generation is inconsistent (score 0.00), indicating operational challenges.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where PHIO ranks in Biotechnology

Phio Pharmaceuticals Corp. ranks #116 of 713 scored companies in Biotechnology by moat score — the top 16%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
112 MacroGenics, Inc. MGNX 60/100 Moderate
113 ArriVent BioPharma, Inc. AVBP 60/100 Moderate
114 Septerna, Inc. SEPN 60/100 Moderate
115 Tarsus Pharmaceuticals, Inc. TARS 60/100 Moderate
116 Phio Pharmaceuticals Corp. PHIO 60/100 Moderate
117 Climb Bio, Inc. CLYM 59/100 Moderate
118 Ascentage Pharma Group Internat AAPG 59/100 Moderate
119 Arrowhead Pharmaceuticals, Inc. ARWR 59/100 Moderate
120 BriaCell Therapeutics Corp. BCTX 59/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How PHIO scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 96 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 40 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 67 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding PHIO's moat

What is Phio Pharmaceuticals Corp.'s moat score?

Phio Pharmaceuticals Corp. (PHIO) scores 60 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #116 of 713 scored companies in Biotechnology, the top 16%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (96/100) and its weakest is Capital Efficiency (40/100).

How does Phio Pharmaceuticals Corp. compare with other Biotechnology companies?

Phio Pharmaceuticals Corp. ranks #116 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Tarsus Pharmaceuticals, Inc. (TARS) at 60 just above it and Climb Bio, Inc. (CLYM) at 59 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Phio Pharmaceuticals Corp. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Phio Pharmaceuticals Corp.?

The Corporate Default template measures 6 defenses, and PHIO scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (96), Capital Efficiency (40), Resilience (67), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000